Skin Cancers

• Participant Clinical Case Discussion: A Case Of Malignant Melanoma Recurrence 10 Years After Initial Immunotherapy
• Congress Highlights 2 - Melanoma
• Human melanoma cells from different disease stages prime amino acid signature of conditional media indicating signalling in the tumor microenvironment
• Pilot Study of Anxiety, Depression, and Quality of Life in Patients with the Diagnosis of Metastatic Uveal Melanoma
• Melanoma with brain metastases. Experience of immunotherapy in a single center.
• EONS Poster - BRAF/MEK-inhibition for patients with metastatic melanoma: towards patient-centered care
• EONS Poster - Supporting melanoma patients and their carers: A qualitative exploration of social interaction between patients, carers and healthcar...
• A Personal Neoantigen Vaccine, NEO-PV-01, with anti-PD1 Induces Broad De Novo Anti-Tumor Immunity in Patients with Metastatic Melanoma, NSCLC, and...
• OpACIN-neo – A Multicenter Phase 2 Study to identify the Optimal neo-Adjuvant Combination scheme of Ipilimumab (IPI) and Nivolumab (NIVO).
• Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with...
• Proffered paper session - Melanoma and other skin tumours - Invited Discussant one LBA TBC, LBA42 and LBA43
• Overall survival at 4 years of follow-up in a phase 3 trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
• KEYNOTE-022 Part 3: Phase 2 Randomized Study of 1L Dabrafenib (D) and Trametinib (T) Plus Pembrolizumab (Pembro) or Placebo (PBO) for BRAF-Mutant A...
• Proffered paper session - Melanoma and other skin tumours - Invited Discussant LBA44 and 1244O
• What is the role of intratumour therapy?
• Emerging prognostic factors in primary melanoma
• Treatment in advanced melanoma patients with a worse prognosis
• Patient treatment resistance in melanoma
• Management of toxicities of immunotherapy - GI toxicity
• Management of toxicities of immunotherapy - Neurotoxicity
• Management of toxicities of immunotherapy - How to treat beyond acute toxicity
• Molecular analysis of NRAS, BRAF, C-KIT, ROS1, ALK and RET alterations in serial biopsies in sinonasal mucosal melanoma
• ATM as a DNA Damage Response Protein in Uveal Melanoma: Association with Clinicopathological Factors and Prognostic Outcome
• Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial
• Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial

• « Previous
• 1
• 2
• ...
• 28
• Next »